Fundraising setback for Stemline as it puts off IPO
23:05 EDT 12 Aug 2012 | SCRIP
New York-based Stemline Therapeutics has decided now is not the right time to go to market, postponing its initial public offering in which it planned to raise up to $42 million by selling 3.5 million shares at $11 to $13 per share (
Original Article: Fundraising setback for Stemline as it puts off IPO
More From BioPortfolio on "Fundraising setback for Stemline as it puts off IPO"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
